Nervous about needles? FDA OKs Janssen injection device for the squeamish
The Food and Drug Administration on Wednesday granted marketing approval to Janssen Pharmaceutical Co.'s Tremfya One-Press, a patient-controlled injector designed for people with moderate-to-severe psoriasis.
Tremfya is Horsham-based Janssen Biotech's biologic treatment approved by the FDA in 2017 for psoriasis, a chronic inflammatory disorder that results in the overproduction of skin cells. The condition causes raised, inflamed, red lesions or plaques — which can result in physical pain and…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Biotechnology | Chronic Pain | Food and Drug Administration (FDA) | Health Management | Marketing | Pain | Pharmaceuticals | Psoriasis | Skin